AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05300659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action for Rehabilitation for Neurological Injury (ARNI)
Description: If randomised to upper limb training, a patient will undertake 10 therapy sessions with an instructor from the Action for Rehabilitation for Neurological Injury (ARNI) program during their hospital stay. The last two ARNI-led sessions will be filmed by a nurse/carer on either their own tablet/phone or an i-pad. Participants in the ARNI group will be encouraged to continue doing their personalized exercises while in hospital and continued at home. They will also be given a task-training board to take home
Study NCT05327088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine, a highly selective α₂ receptor agonist, has a sympatholytic, sedative and opioid sparing effect.
Study NCT05327088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: Nalbuphine, a derivative of 14-hydroxymorphine is a strong analgesic with mixed k agonist and µ antagonist properties. The analgesic potency of nalbuphine has been found to be equal to morphine
Study NCT05961540 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional care
Description: 1. Instruct parents to follow up with the baby at the doctor's appointment.~2. Provide telephone follow-up visits at 1 month, 3 months, and 6 months of age to assess the baby's feeding and physical development (height and weight).
Study NCT05961540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding behavioural intervention for mothers of infants with CHD
Description: Based on the Behavioural Change Wheel theory,the intervention program is developed and implemented to promote the change in breastfeeding behavior of mothers with CHD infants,so as to improve the exclusive breastfeeding rate of this population.Specific programs include:~1. Evaluate signs of hunger and satiety in infants.~2. Family visits, face-to-face guidance on breastfeeding skills, breast milk storage and management.~3. Training methods for promoting breast milk secretion.~4. To explain common feeding difficulties manifestations and treatment methods in infants with CHD.~5. Establish a breastfeeding promotion alliance.~6. Teach mothers to weigh their babies before and after breastfeeding to determine breast milk intake.~7. Assess and guide the growth and development of infants with CHD.
Study NCT04887506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVT-45
Description: 250 mg abiraterone acetate granules for oral suspension in a sachet, reconstituted in water or specified fruit juice (orange juice), administered twice daily.
Study NCT04887506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zytiga
Description: 500 mg tablet, two tablets administered once daily
Study NCT04887506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: mCSPC patients received 5 mg orally once daily. mCRPC patients received 5 mg orally twice daily.
Study NCT04887506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: mCSPC patients received 5 mg orally once daily. mCRPC patients received 5 mg orally twice daily.
Study NCT05440747 — intervention group
Intervention type: OTHER
Intervention: TFR(Treatment-Free Remission)
Description: Withdrawal TKIs(Tyrosine kinase inhibitors: Imatinib or Flumatinib or Nilotinb or Dasatinib)
Study NCT05891717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Twice per week for 8 weeks. Total 16 sessions will given.
Study NCT05891717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility training
Description: Twice per week for 8 weeks. Total 16 sessions will given.
Study NCT04975503 — intervention group
Intervention type: OTHER
Intervention: Observing cardiovascular risk factors
Description: Documenting the presence or absence of CVD risk factors in each participant.
Study NCT03531476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Chronic Pain Management Program
Description: With the support of a study therapist, the participant will be enrolled in a 5 week self-directed pain management program. The study therapist is a registered health professional. The program will consist of 5 weeks of mindfulness training. The mindfulness training focuses on the basics of mindfulness-based interventions including body, emotions, sensations, thoughts, compassion, pain and stress management.
Study NCT06274606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: Previously sedentary adults awaiting bariatric surgery will be randomized to either an Exercise group (EX-group) or Standard care only group (SC-group) for 8 weeks. Outcome visits will occur before the exercise intervention, after the exercise intervention, and after surgery
Study NCT06442124 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography (EMG)
Description: The present study will be conducted to add a new information to the body of knowledge of physical therapy profession as it will investigate the effect of BMI on gluteus maximum activity recorded by EMG in adulthood with sacroiliac dysfunction
Study NCT04878549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 5-gene transcription signature
Description: This is a prospective multisite diagnostic evaluation study to assess a novel approach to the diagnosis of enteric fever. The index test of host gene transcription responses by a 5 gene-signature will be compared to the reference test of blood culture confirmation for a diagnosis of enteric fever in patients with AUFI.
Study NCT06432673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-258 Oral solution
Description: Oral solution
Study NCT06432673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-258 Oral capsule
Description: Oral capsule
Study NCT04996433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inpatient CBASP individual therapy
Description: During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual CBASP therapy sessions (duration: 50 min per session).
Study NCT04996433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inpatient CBASP group therapy
Description: During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 CBASP group therapy sessions (duration: 100 min per session).
Study NCT04996433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inpatient CBASP nurse contact
Description: During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP nurse contact (duration: 30 min per session).
Study NCT04996433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inpatient CBASP exercise therapy
Description: During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP exercise therapy (duration: 75 min per session).
Study NCT04996433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: outpatient CBASP group therapy
Description: During the 6-week outpatient treatment all patients in this arm will receive 1 CBASP group therapy session (duration: 100 min per session).
Study NCT04996433 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: inpatient BA individual therapy
Description: During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual BA therapy sessions (duration: 50 min per session).
Study NCT04996433 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: inpatient BA group therapy
Description: During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 BA group therapy sessions (duration: 100 min per session).
Study NCT04996433 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: inpatient BA nurse contact
Description: During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA nurse contact (duration: 30 min per session)
Study NCT04996433 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: inpatient BA exercise therapy
Description: During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA exercise therapy (duration: 75 min per session).
Study NCT04996433 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: outpatient BA group therapy
Description: During the 6-week outpatient treatment all patients in this arm will receive 1 BA group therapy session (duration: 100 min per session).
Study NCT04996433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: algorithm-based study medication
Description: All patients will receive an optimized, algorithm-based antidepressant medication following the current S3-Guidelines on Unipolar Depression. In case of nonresponse:~* 1st line dose escalation (if appropriate)~* 2nd line lithium augmentation~* 3rd line augmentation with 2nd generation antipsychotics or evidence-based combinations of antidepressants~* 4th line change of antidepressant.
Study NCT04996433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: algorithm-based study medication
Description: All patients will receive an optimized, algorithm-based antidepressant medication following the current S3-Guidelines on Unipolar Depression. In case of nonresponse:~* 1st line dose escalation (if appropriate)~* 2nd line lithium augmentation~* 3rd line augmentation with 2nd generation antipsychotics or evidence-based combinations of antidepressants~* 4th line change of antidepressant.
Study NCT06211777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
Study NCT06211777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
Study NCT06211777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06211777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT05321199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to be effective in reducing blood loss and the need for transfusions after several orthopaedic surgeries.
Study NCT04618367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks
Study NCT04618367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study NCT04618367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg intravenously every 3weeks
Study NCT05473611 — intervention group
Intervention type: PROCEDURE
Intervention: closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring
Description: closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring
Study NCT06189378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclusion of patient-provided pictures into blood pressure diaries
Description: Patient-provided pictures with positive meaning were included into blood pressure diaries
Study NCT06189378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional blood pressure diary
Description: Conventional blood pressure diary
Study NCT05415566 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: toy nebulizer and toy mask
Description: The treatment was administered using therapeutic play.
Study NCT06131021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin belongs to the penicillin category, and it is a commonly prescribed broad-spectrum antibiotic as a periodontal treatment adjunct.
Study NCT06131021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole is effective against anaerobic bacteria, and it is often combined with Amoxicillin for an enhanced antimicrobial effect as a periodontal treatment adjunct.
Study NCT06131021 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in identical drug-safe vials with capsules identical in appearance to the active drugs
Study NCT05289765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A natural neutral Ecological Extra Virgin Olive Oil based gel
Description: A natural neutral Ecological Extra Virgin Olive Oil based gel will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline.
Study NCT05289765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products
Description: A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline
Study NCT06320132 — intervention group
Intervention type: OTHER
Intervention: Treatment of spontaneous intracranial hemorrhage
Description: Data collection of therapeutic approach, including radiological, medical, surgical therapies.
Study NCT05524662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-785-7
Description: Treatment with BTL-785F device (BTL-785-7 applicator) for non-invasive facial rejuvenation.
Study NCT05827094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: The main mobile intervention features. Tracking and immediate feedback: Pressing the icon launches a short series of questions with multiple-choice response options focusing on recent meals . The survey items are modeled after the 14-item Mediterranean Adherence Screener using simplified language and intuitive visuals to lower cognitive load. Based on responses to the survey, the app provides an intuitive visualization of the survey results, personalized feedback, and recipes on how to improve the person's diet. On-demand resources: individuals are able to access on-demand resources about the MedD diet, its benefits, and best dietary practices. The recipe page includes a personalized list of simple breakfast, lunch, dinner, and snack recipes based on the survey results with step by step instructions on how to prepare Mediterranean foods. In-app messaging: Individuals are able to receive notifications and send and receive messages.
Study NCT05827094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants randomly allocated to the control group will receive educational materials on healthy eating, as provided on the NIA web page (https://www.nia.nih.gov/health/healthy-eating).
Study NCT06479928 — intervention group
Intervention type: OTHER
Intervention: delivery mode
Description: Based on delivery mode, we will divide them into two groups, including Cesarean section and Natural delivery.
Study NCT06384105 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: frames per second
Description: Other settings for frames per second
Study NCT05474053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg (Brilique)
Description: compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
Study NCT05474053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg (Ticaloguard)
Description: compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
Study NCT06289595 — intervention group
Intervention type: DEVICE
Intervention: PBM Ortho device
Description: Device emits light for photobiomodulation (light therapy).
Study NCT05000736 — intervention group
Intervention type: DRUG
Intervention: palbociclib + aromatase inhibitor
Description: palbociclib + aromatase inhibitor therapy
Study NCT05000736 — intervention group
Intervention type: DRUG
Intervention: fulvestrant
Description: fulvestrant monotherapy
Study NCT06311071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: calcium score
Description: Calcium score of coronaries obtained fro coronary CT angiography
Study NCT06311071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive coronary angiography
Description: Invasive coronary angiography from radial artery with contrast injection
Study NCT05124483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AKS-452X
Description: subcutaneous injection of 90 µg AKS-452X
Study NCT05722886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Adult participants will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric participants with a body weight ≥40 kg and who are able to swallow the capsules will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent.
Study NCT05722886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Adult participants will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric participants will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent.
Study NCT05722886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Adult and paediatric participants with body surface area (BSA) ≥1.51 m\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric participants will receive a dose adjusted for BSA. Each cycle of treatment will consist of 28 days and participants may continue until disease progression, unacceptable toxicity or withdrawal of consent.
Study NCT05722886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with pertuzumab
Description: The initial loading dose of trastuzumab is 8 mg/kg body weight administered intravenously every 21 days followed thereafter by a maintenance dose of 6 mg/kg body weight.~The initial loading dose of pertuzumab is 840 mg administered intravenously every 21 days followed thereafter by a maintenance dose of 420 mg.~Participants may continue until disease progression, unacceptable toxicity or withdrawal of consent.